The Senate Health committee on Tuesday advanced to the full Senate the nomination of Dr. Robert Califf to be commissioner of the Food and Drug Administration.
He has had relatively smooth sailing in the confirmation process and received praise from both sides of the aisle on Tuesday.
Chairman Lamar AlexanderLamar AlexanderRepublicans play clean up on Trump's foreign policy GOP's ObamaCare talking points leave many questions unanswered Overnight Regulation: Trump's new Labor pick | Trump undoes Obama coal mining rule MORE (R-Tenn.) touted Califf's “impressive” qualifications and noted that having a confirmed head of the FDA is important at a time when so much “exciting science” and possible new medical breakthroughs are happening.
What blowback Califf has received came from the left.
Sen. Bernie SandersBernie SandersDrug importation from other countries will save dollars and lives Sanders: Trump a 'pathological liar' Buttigieg endorsed by ex-treasurer in DNC race MORE (I-Vt.), a presidential candidate, previously announced he will oppose the nomination, saying that Califf’s ties to the drug industry are too tight. Califf faced some scrutiny over industry-funded studies while at Duke.
“His extensive ties to the pharmaceutical industry give me no reason to believe that he would make the FDA work for ordinary Americans,” Sanders said in a statement on Tuesday after voting against the nomination by proxy.
However, Sen. Patty MurrayPatty MurraySenate Dems move to nix Trump's deportation order Oprah's network provides Senate with tape of abuse allegations by Puzder's ex-wife: report How many GOP senators will stand up to megadonor DeVos? Just 2. MORE (Wash.), the committee’s top Democrat, on Tuesday defended Califf and applauded his “commitment to transparency in relationships with industry.”
Califf's nomination comes as the FDA is in the spotlight. The health panel is working on companion legislation to the House-passed 21st Century Cures Act, which aims to speed up the agency's approval process for new drugs and boost funding medical research.
Alexander last year said that the committee would finish its work on the bill by the end of 2015, but the panel has not released a bill, much less advanced it to the full Senate.
Still, Alexander said Tuesday that it is a priority in the new year. “We should finish our work on this bill, and I’m committed to doing it in a bipartisan way that allows amendments,” he said.
Controversy over high drug prices is also intensifying. Sen. Sheldon WhitehouseSheldon WhitehousePruitt confirmation sets stage for Trump EPA assault Senate Dems ask DHS inspector general for probe of Trump’s business arrangement Senate confirms Pruitt to lead EPA MORE (D-R.I.) called for action to deal with drug companies that hike the prices for drugs that have little competition, often because they treat rare diseases. Sen. Susan CollinsSusan CollinsPruitt sworn in as EPA chief Comey meets Intel senators amid uproar over Trump-Russia ties EPA breaks Twitter silence to congratulate new head MORE (R-Maine) has also been tackling the issue with a Senate Aging Committee investigation.
One speed bump in the way of Califf’s nomination could be concerns from Sen. Lisa MurkowskiLisa MurkowskiPublic lands dispute costs Utah a major trade show Oprah's network provides Senate with tape of abuse allegations by Puzder's ex-wife: report More than 100 groups back Puzder for Labor secretary MORE (R-Alaska) over the FDA’s approval of genetically modified salmon as food.
She said Tuesday that she will push for clear labeling guidelines so consumers are aware that the fish is genetically modified.
Alexander, though, responded that he wants the full Senate to confirm Califf soon.
“If there are issues, I hope those conversations can be speedy,” he said.